In 1995, a study found that MVP, also known as the drug resistance-related protein (LRP), is the human major vault protein, and that its overexpression leads to a poor response to chemotherapy in acute myeloid leukemia and ovarian carcinoma (7). This evidence concerns the gene MVP and ovarian carcinoma.